Company intelligence / Profile preview

Surgalign

Ownership: Public · SRGAQ
Employees: ~163
Development stage: Other

Overview

Surgalign developed a broad portfolio of spinal implants and biomaterials. Its flagship HOLO Portal AI/AR-guided surgical system won the "Best New Spine Technology Award" in October 2022. The company filed for Chapter 11 bankruptcy in June 2023 after divesting several product lines to Xtant Medical. It continued to focus on its AI-driven platforms but its independent operations appear to have ceased or been significantly reduced since then.

Therapeutic areas: RheumatologyNeurology
Modalities: DeviceDigital surgery platform (AI/AR-based guidance system)Biomaterial products
Industry: Surgical Medical Devices

Partnerships

No major pharma partnerships reported; distribution via network of independent distributors globally.

Beyond the preview

Go deeper on Surgalign.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Surgalign.

Explore the full profile